Cash Flow BioCryst Pharmaceuticals, Inc. Cash flow Statement
Figures in Million
Consolidated Cash Flow Results
Dec'25
Dec'24
Dec'23
Dec'22
Dec'21
Dec'20
No of Months
12
12
12
12
12
12
Profit Before Tax
267.00
-86.00
-226.00
-244.00
-181.00
-182.00
Adjustment
0.00
0.00
0.00
0.00
0.00
0.00
Changes In working Capital
-56.00
-87.00
-32.00
-58.00
8.00
26.00
Cash Flow after changes in Working Capital
0.00
0.00
0.00
0.00
0.00
0.00
Cash Flow from Operating Activities
329.00
-52.00
-95.00
-161.00
-142.00
-137.00
Cash Flow from Investing Activities
-13.00
52.00
-131.00
-128.00
15.00
-6.00
Cash Flow from Financing Activities
-332.00
-5.00
32.00
88.00
359.00
302.00
Net Cash Inflow / Outflow
-14.00
-6.00
-193.00
-201.00
233.00
158.00
Opening Cash & Cash Equivalents
0.00
0.00
0.00
0.00
0.00
0.00
Cash & Cash Equivalent on Amalgamation / Take over / Merger
0.00
0.00
0.00
0.00
0.00
0.00
Cash & Cash Equivalent of Subsidiaries under liquidations
0.00
0.00
0.00
0.00
0.00
0.00
Translation adjustment on reserves / op cash balances foreign subsidiaries
0.00
0.00
0.00
0.00
0.00
0.00
Effect of Foreign Exchange Fluctuations
1.00
0.00
0.00
0.00
0.00
0.00
Closing Cash & Cash Equivalent
0.00
0.00
0.00
0.00
0.00
0.00
Figures in USD Million
Seasonal companies are compared with the same quarter last year
Seasonal companies are compared with the same quarter last year
Compare Cash Flow Results of BioCryst Pharmaceuticals, Inc.
Figures in Million
consolidated Cash Flow Results
Change(USD)
Change(%)
Profit Before Tax
267.391
-353
620.00
175.75%
Adjustment
0
0
0.00
0.00%
Changes In working Capital
-56.898
-194
138.00
70.67%
Cash Flow after changes in Working Capital
0
0
0.00
0.00%
Cash Flow from Operating Activities
329.88
-482
811.00
168.44%
Cash Flow from Investing Activities
-13.694
66
-79.00
-120.75%
Cash Flow from Financing Activities
-332.442
488
-820.00
-168.12%
Net Cash Inflow / Outflow
-14.986
72
-86.00
-120.81%
Opening Cash & Cash Equivalents
0
0
0.00
0.00%
Cash & Cash Equivalent on Amalgamation / Take over / Merger
0
0
0.00
0.00%
Cash & Cash Equivalent of Subsidiaries under liquidations
0
0
0.00
0.00%
Translation adjustment on reserves / op cash balances foreign subsidiaries
0
0
0.00
0.00%
Effect of Foreign Exchange Fluctuations
1.27
0
1.00
0.00%
Closing Cash & Cash Equivalent
0
0
0.00
0.00%
Cash Flow - Snapshot (Consolidated) - Dec'25
YoY Growth in year ended Dec 2025 is 734.14% vs 45.32% in Dec 2024
Dec'25
Dec'24
Change(%)
Cash Flow from Operating Activities
329.88
-52.02
734.14%
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
